Cart
sales@molnova.com
Legumain inhibitor 1
CAS No. 2361157-34-6
Legumain inhibitor 1( —— )
Catalog No. M35166 CAS No. 2361157-34-6
Legumain inhibitor 1 is a highly potent and specific Legumain inhibitor with potential anticancer activity for cancer research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 454 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLegumain inhibitor 1
-
NoteResearch use only, not for human use.
-
Brief DescriptionLegumain inhibitor 1 is a highly potent and specific Legumain inhibitor with potential anticancer activity for cancer research.
-
DescriptionLegumain inhibitor 1 is a potent and selective Legumain inhibitor with an IC50 of 3.6 nM. Legumain inhibitor 1 can be used for cancer research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayNeuroscience
-
TargetGamma-secretase
-
RecptorGamma-secretase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2361157-34-6
-
Formula Weight467.54
-
Molecular FormulaC23H25N5O4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 40 mg/mL (85.55 mM; Ultrasonic )
-
SMILESCn1ncc2cc(ccc12)-c1ccc(cc1)S(=O)(=O)CC(C)(C)C(=O)N[C@@H](CC(N)=O)C#N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Sharon L Eddie, et al. Identification and SAR exploration of a novel series of Legumain inhibitors. Bioorg Med Chem Lett. 2019 Jun 15;29(12):1546-1548.?
molnova catalog
related products
-
Demcizumab
Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody and a potent Notch pathway inhibitor, demonstrating efficacy in various cancer models both as a monotherapy and in conjunction with chemotherapy agents.
-
Monomethyl auristati...
Monomethyl auristatin E (MMAE), an antimitotic agent, inhibits cell division by blocking the polymerization of tubulin and also has inhibition of antibody-drug conjugates (ADCs) activity.
-
PEAQX
PEAQX(NVP-AAM 077) is an effective and orally available NMDA antagonist. It can inhibit human NMDA receptors for 1A/2A(IC50: 270 nM), rather than 1A/2B(29, 600 nM).
